Background -Antimicrobial-resistant bacteria are increasingly isolated from veterinary patients.
Introduction
Staphylococci are normal mucosal and skin commensals affecting people and other animals. 1 The main coagulase positive Staphylococcus (CoPS) species in humans is S. aureus 2 and in dogs is S. pseudintermedius, 3 previously S. intermedius. 4 Staphylococcus pseudintermedius is the most frequent cause of canine pyoderma. 5, 6 The population prevalence of mucosal S. pseudintermedius carriage in healthy dogs is between 11% and 87.4%; [7] [8] [9] [10] [11] [12] with increased carriage in dogs with pyoderma. 13, 14 Fewer healthy dogs carry S. aureus (6.5% to 14%) 7, 8, 11, 12, 15 and such isolates are likely to originate from in-contact humans. 16 In addition, coagulase negative staphylococci (CoNS) are common mucosal commensals in humans and other animals, with a population prevalence in dogs between 38% (isolated from nasal swabs) 12 and 95% (from nasal and perineal swabs). 11 Meticillin-resistant (MR) and multidrug-resistant (MDR) staphylococci are increasingly isolated from dogs, 17 rendering many antimicrobials ineffective. Meticillin-resistant staphylococci (MRS) carry the mecA gene which encodes an altered penicillin-binding protein (PBP2a) and confers resistance to all beta-lactam antimicrobials. 18 The mecA gene is carried on a large mobile genetic element (MGE), the staphylococcal cassette chromosome mec (SCCmec), which can be transferred horizontally between staphylococci. 19 It has been suggested 20 that CoNS (commonly MR and/or MDR 21, 22 ), were the original source of the mecA gene and may act as reservoirs of AMR genes for CoPS. [22] [23] [24] [25] SCCmec may also carry resistance genes for other antimicrobials 26 and MRS can harbour other MGEs and chromosomal mutations giving rise to MDR. Hence, MRS are frequently MDR and commonly fluoroquinolone-resistant (FQR). 24 The population prevalence found in most studies of meticillin-resistant S. pseudintermedius (MRSP) carriage in healthy dogs is between 0 and 4.5%, 8, 11, 12, [27] [28] [29] [30] although prevalence can be higher, between 8 and 34% 8, 14, 31, 32 and up to 66% in one Japanese study 33 in dogs with skin disease and/or exposed to other potential risk factors. Reported risk factors for mucosal carriage of, or infection with, MRS in dogs include antimicrobial therapy, contact with veterinary premises and hospital admissions. 31, [34] [35] [36] [37] [38] [39] [40] Similar risk factors have been reported or proposed for MR S. aureus (MRSA) and MR coagulase negative staphylococci (MR-CoNS) carriage in humans; 23, 38 the MR-CoNS population prevalence in healthy dogs is reported to be up to 42%. 11, 12, 30 Carriage may lead to transfer of staphylococci between individuals or to the environment, with long-term persistence being reported in both circumstances. [41] [42] [43] [44] [45] Most previous studies that have examined MRS risk factors for dogs have found either no association with antimicrobial therapy or reported a general association; none have examined longitudinal carriage. This study aimed to: (i) examine AMR mucosal staphylococcal longitudinal carriage prevalence after antimicrobial administration; (ii) determine the risk factors for detection of such bacteria; and (iii) compare the impact of commonly used antimicrobials on the selection and persistence of AMR.
Materials and Methods

Study population
Dogs attending veterinary consultations at three centres (a first opinion clinic, a referral practice, and a centre with both first opinion and referral patients), in Northwest England between June 2011 and September 2012 were recruited for the study. The inclusion criteria were: diagnosis of a bacterial infection (skin, soft tissue, urinary tract, dental, respiratory tract, orthopaedic, gastrointestinal or ocular) and a requirement for systemic antimicrobial therapy with one of six antimicrobials authorized for use in dogs in the UK [cefalexin (CFX), clavulanate-amoxicillin (AC), cefovecin (CVN) , clindamycin (CD) or a fluoroquinolone (FQ) (enrofloxacin or marbofloxacin)]. Treatment groups were based on the antimicrobial prescribed. Exclusion criteria were: antimicrobial therapy or admission within three months prior to consultation and dogs aged less than 12 months (FQs are contraindicated in this group). Dogs also were excluded if they were administered additional systemic antimicrobials during the course of the study. Samples were collected pre-treatment, immediately posttreatment and at one and three months post-treatment. The University Veterinary Ethics Committee approved the study protocol.
Staphylococcal isolation
One nasal swab and one perineal swab was collected from each dog (Copan Eswab LQ Amies Minitip Nylon Flocked Applicator; Appleton Woods, Birmingham, UK) at each time point. A sterile swab was inserted 5 mm into one nostril and a second swab rubbed on the skin of the perineum for 5 s before being placed in Amies transport media, stored at 4°C, and processed within 36 h of collection.
Each swab was separately incubated aerobically overnight at 37°C in nutrient broth with 6.5% sodium chloride. The overnight broth for each swab (one nasal and one perineal sample per dog) was cultured on mannitol salt agar, oxacillin resistance screening agar supplemented with 2 lg/mL of oxacillin and Columbia 5% horse blood agar (CAB), and incubated aerobically overnight at 37°C. Several isolates of different morphologies, but resembling a staphylococcal phenotype, were selected from each agar plate (six agar plates per sample) and sub-cultured onto CAB for aerobic overnight incubation at 37°C. Fresh staphylococcal cultures on CAB were subjected to Gram stain (Sigma-Aldrich; Gillingham, UK) tested for catalase (Sigma-Aldrich) and free coagulase production (Rabbit plasma, Pro-Lab; Bromborough, UK) according to the manufacturer's instructions. Isolates were stored at À80°C in Microbank vials (Pro-Lab) for further processing. All culture media were obtained from LabM Ltd. (Bury, UK).
Antimicrobial susceptibility testing
Prior to cryopreservation, disc diffusion testing was performed on all confirmed Staphylococcus species isolates in accordance with accepted standards, 46 as described previously, 11 with the following discs: 1 lg oxacillin, 1 lg ciprofloxacin (screening for FQ resistance), 10 lg gentamicin, 10 lg fusidic acid, 30 lg CFX, 30 lg CVN, 25 lg trimethoprim-sulfamethoxazole, 10 lg tetracycline, 2 lg CD and 5 lg vancomycin. All discs were purchased from MAST Group Ltd., Liverpool, UK, except for CVN, which were obtained from Oxoid (Basingstoke, UK). The reference strain S. aureus ATCCâ25923 (LGC Standards; Teddington, UK) was used for quality control of zone diameter determinations.
PCR for nuc and mecA genes
Prior to cryopreservation, DNA extraction was performed as previously described. 11 PCR assays to detect the presence of the nuc genes of S. pseudintermedius, S. aureus and S. schleiferi were performed on all CoPS 47 using Qiagenâ Multiplex PCR Mix (Qiagen; Crawley, UK). PCR assays also were used to detect the presence of the mecA gene in staphylococcal isolates that were phenotypically resistant to oxacillin 48 
Prevalence of staphylococci and resistance
Staphylococci were classed as resistant or not resistant based on the Clinical Laboratory Standards Institute (CLSI) guidelines 2013. 46 As CLSI standards were not available for interpretation of ciprofloxacin and fusidic acid, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) zone diameter interpretive standards were used. 49 The breakpoints for interpretation of oxacillin resistance were a zone of inhibition of ≤17 mm for S. pseudintermedius 50 and CoNS, and ≤10 mm for S. aureus. A sample was classified as AMR if it had at least one AMR staphylococcal isolate. The percentage (with 95% confidence intervals) of samples with CoPS, CoNS, S. pseudintermedius, S. aureus, S. schleiferi subspecies coagulans or with 'no growth' and the percentage of samples with staphylococci resistant to each tested antimicrobial, MRS (phenotypic oxacillin resistance and carriage of the mecA gene) and MDR (resistance to three or more antimicrobial classes) 51 were calculated at each sample time point for each treatment group and treatment overall using Clopper-Pearson exact interval. 52 
Statistical analysis
A questionnaire, examining potential risk factors for the carriage of AMR bacteria was administered at the start of the study and for each follow-up sample. Data were collected describing patient signalment, diet, previous veterinary history (including previous antimicrobial therapy and veterinary admission), the presence, number and type of incontact pets, previous medical history of the household (including antimicrobial therapy or hospitalization of humans or other pets) and whether any household member worked with farm animals or in human or veterinary healthcare. The attending veterinary surgeon also completed a one page questionnaire confirming the diagnosis, the prescribed antimicrobial and therapeutic regime, and any previous antimicrobial therapy within the last 12 months. Independent risk factor variables were created from information obtained from the owner and veterinary surgeon questionnaires. Except for the age of the dog, all variables were dichotomous or categorical in nature. The variables 'treatment duration' and 'body weight' were divided into three categories: ≤1 week, >1 week but ≤3 weeks, and >3 weeks; and small (<11 kg), medium (11-20 kg) and large (>20 kg), respectively. Samples were recruited from three veterinary practices (centres 1, 2 and 3). The type of veterinary consultation was divided into two categories: first opinion and referral. Initial statistical analyses included Spearman's rho to examine risk factor variable correlation. Differences between treatment groups at pre-treatment for each risk factor were investigated using Pearson's chi-square or Fisher's exact tests (if n < 5) for categorical variables or one-way between-groups ANOVA for continuous age data ( Table 1 ). Multivariable logistic regression was then used to investigate any differences in antimicrobial resistance outcomes between treatment groups at pre-treatment, after accounting for other independent variables. Statistical tests were performed using the SPSS software package (SPSS 20.0 for Mac, SPSS Inc; Chicago, IL, USA).
In order to examine the effect of treatment-group/time point, and other independent variables on the presence of resistance outcomes (presence or absence of CoPS, MRS, MDR or FQR in mucosal staphylococci), data were analysed using multilevel logistic regression models with a binomial distribution and logit link function. Due to repeated samples over time, data were clustered within dogs (level two units) and this clustering was accounted for by inclusion of dog as a random intercept in all models. Swab samples were considered the level one unit of interest. All dogs at pre-treatment were classed as untreated (n = 127 dogs). In total, in addition to pre- (24) 17 (23) 14 (19) 17 (23) 9 (12) 75 (59) 0.925 Female 13 (25) 12 (23) 12 (23) 11 (21) 4 (8) 52 (41 (2) 22 (40) 11 (20) 13 (24) 55 (43) A diagnosis of pyoderma was made at enrolment 27 (33) 3 (4) 25 (31) 15 (18) 12 (15) treatment (the reference time point), there were 15 categories created to account for the different combinations of time (n = 3) and treatment group (n = 5). Initially all variables were analysed using unadjusted multilevel models. Those that showed some association with each outcome on unadjusted analysis (P-value <0.25) 53 were considered for incorporation into a final multilevel, multivariable model. Treatment group/time point were always retained in final models. Final models were constructed using a manual backwards stepwise procedure where variables with a Wald P-value <0.05 were retained. Once a final multivariable model was produced, all variables that were significantly (P < 0.05) different between treatment groups at pre-treatment were forced back into the model to assess their effect on remaining variables, and in particular, treatment group. Multilevel models were analysed using the MLwiN statistical software package (MLwiN v2.28 Centre for Multilevel Modelling, University of Bristol; https://www.bristol.ac.uk/cmm/software/mlwin/). Univariable and multivariable calculations used penalized quasi-likelihood (PQL) estimates (second-order PQL for all outcomes). First-order interaction terms were tested for all variables remaining in the final models. The residuals (AE 1.96 standard deviation) were calculated and presented in ranked order in caterpillar plots for each dog, to check for outliers. If present, outliers were temporarily removed and the models were rerun to assess the impact upon results.
Results
Study population
One hundred and twenty seven dogs were enrolled from three centres: 1 (n = 43), 2 (n = 52) and 3 (n = 32), which represented 72 first opinion and 55 referral cases. The dogs were treated with: CFX (n = 31), AC (n = 29), CVN (n = 26), CD (n = 28) or a FQ (n = 13). Treatment was prescribed for ≤1 week in 33 dogs, >1 week but ≤3 weeks in 48 dogs and >3 weeks in 46 dogs. Indication-based prescription consisted of pyoderma (n = 81 dogs), bite wound (n = 4), post-surgical infection/prophylaxis (n = 8), infected skin tumour/cyst (n = 2), gingivitis (n = 9), anal sac abscess (n = 4), otitis externa (n = 2), pedal abscess/nail bed injury (n = 4), respiratory tract infection (n = 2), corneal ulcer (n = 1), gastritis (n = 1) or urinary tract infection (n = 9). The dogs were aged from 12 to 204 months (mean = 62 months) with 75 males and 52 females, 21 small, 16 medium and 90 large dogs. One hundred and twenty seven dogs yielded samples at pre-treatment and immediately post-treatment, 106 dogs had samples taken at one month and 103 dogs at three months post-treatment, respectively, resulting in a total of 463 samples ( Table 2) .
Owners of 24 dogs worked in health care environments; four owners in veterinary healthcare; 18 owners in human healthcare (hospital, GP surgery, community nursing, paramedical, pharmaceutical, research or nursing home staff); and two owners in undefined healthcare. Missing samples from one month post-treatment (n = 21) were due to prescription of further antimicrobials (n = 6), euthanasia or death due to unrelated reasons (n = 2), or owner noncompliance (n = 13). Missing samples from three months post-treatment (n = 24) were due to prescription of further antimicrobial courses (n = 10), euthanasia or death due to unrelated reasons (n = 3), re-homing (n = 3) or owner noncompliance (n = 8).
Prevalence of staphylococci Overall, staphylococci were isolated in 88% of samples from 99% of dogs during the whole study period. These included CoNS, isolated in 59% of samples from 93% of dogs, and CoPS, isolated in 62% of samples from 87% of dogs. CoPS isolates were S. aureus, isolated in 9% of samples from 21% of dogs, S. schleiferi subspecies coagulans, isolated in 3% of samples from 7% of dogs and S. pseudintermedius, isolated in 56% of samples from 83% of dogs (Table S1 ); 67% of samples positive for S. pseudintermedius were isolated from the nares and 79% were isolated from the perineum (data not shown). Changes in the percentage of samples with CoPS, S. pseudintermedius or CoNS during the study period are shown in Figure 1 and Table S1 (Table S1 also shows samples with 'no staphylococcal growth').
Prevalence of antimicrobial resistance
During the whole study period, MRS were isolated in 26% of samples from 63% of dogs; however, MR-CoPS were only isolated in 10% dogs. Of the MR-CoPS, 11 dogs carried MRSP and two dogs carried MRSA; all S. schleiferi subspecies coagulans were meticillin-susceptible. Of the 11 dogs with MRSP, the first isolation was immediately post-treatment in two dogs, and at one month post-treatment in four dogs. After initial isolation, MRSP also was isolated in subsequent samples in four dogs (Table S2) . Changes in the percentage of samples with MRS, MDR and FQR at different time points are shown in Figure 2 , and for CD and trimethoprim sulfamethoxazole in Figure S1 .
Multilevel logistic regression
There were significant differences at pre-treatment, between treatment groups (CFX, AC, CVN, CD or FQs) in: age, weight, treatment duration, recruitment site, type of veterinary consultation, whether a 'diagnosis of pyoderma' was made, previous systemic antimicrobial treatment, in-contacts admitted to hospital/veterinary premises, and dogs regularly eating animal stools (Table 1 ). There were, however, no significant differences among pre-treatment variables for each treatment group for each resistance outcome (MRS, MDR or FQR) after accounting for all variables in multivariable models.
Multilevel multivariable model results suggested that individual treatment groups, CFX, CVN and CD, were significantly associated with decreased CoPS isolation immediately post-treatment. Furthermore, fluoroquinolone therapy was a significant risk for the detection of MRS, MDR or FQR staphylococci, and CFX was a risk for the detection of MDR staphylococci immediately post-treatment (Tables 3 and 4) . At one month post-treatment, there were no significant differences compared to all pre-treatment samples, for any treatment group or AMR outcome measure other than an increased risk for the detection of MDR staphylococci after fluoroquinolone treatment, and decreased CoPS after clindamycin. At three months post-treatment, the only significant difference, compared to all pretreatment samples, was increased risk of MDR staphylococci following CFX treatment.
Other results from the multivariable multilevel models: dogs living in a multi-dog household had significantly decreased MRS compared to single-dog households; small and medium dogs compared to large dogs had significantly increased FQR staphylococci; female dogs, dogs that regularly ate animal stools or dogs that lived with in-contacts admitted to hospital/veterinary premises had significantly increased carriage of MDR staphylococci; recruitment site significantly impacted on CoPS detection with reduced isolation in dogs from Centre 3 (referral only) than Centre 1 (mixed referral and first opinion); and a 'diagnosis of pyoderma' significantly increased the risk of identifying CoPS (Tables 3 and 4) .
Discussion
This study is the first prospective, longitudinal survey to examine the effects of different routine antibiotic therapies on canine mucosal staphylococci and the development of AMR. The results suggest that levels of resistance increased in staphylococci immediately posttreatment for most of the antibiotics investigated, and at the same time the level of CoPS decreased. In addition, levels of AMR returned to pre-treatment prevalence by one to three months post-treatment, for most antibiotics and types of resistance.
Prevalence of staphylococci Mucosal CoNS and CoPS, including S. pseudintermedius (93%) and S. aureus (21%), were isolated from a high proportion of dogs during the study period. Staphylococcus pseudintermedius has been isolated from up to 87.4% and S. aureus from up to 14% of healthy dogs. 7, 10 Repeated sampling is likely to have yielded a high prevalence of staphylococci in this study; in particular S. pseudintermedius carriage in dogs has been reported to be diverse and changing over time 9, 41 and could be missed with cross-sectional sampling. Moreover, the majority of enrolled dogs were diagnosed with pyoderma, which may have increased detection of mucosal staphylococci, 36 and in particular, S. pseudintermedius. 13, 14 The overall study prevalence of CoNS which we have identified (93%) matches previous results (95%, from n = 73 individuals), using the same methodology in healthy dogs; 11 this is much higher (38%) than the prevalence in a larger cross-sectional study (n = 724) in which only the nares were sampled using different methodology. 12 A previous study also reported improved sensitivity to detect canine staphylococcal carriage by sampling two anatomical sites (in particular the mouth along with the perineum or nares). 54 The high prevalence detected in this study is not unexpected for commensal bacteria.
The decrease in CoPS and increase in CoNS noted immediately post-treatment could be due to inhibition of potentially more AMR-susceptible CoPS and selection of more AMR-resistant CoNS. CoNS are more commonly MR and MDR, 21, 22 so one concern is that they may act as reservoirs of AMR genes for CoPS 22, 24 during co-colonization. Although CoNS are often thought to be nonpathogenic compared to CoPS, CoNS can possess virulence factors, and have been reported to cause serious disease in both human and animal hosts. 21, 22 Furthermore, coagulase negative S. schleiferi subspecies schleiferi has been increasingly isolated from infections in dogs, 55 particularly following antimicrobial therapy. However, in the present study we did not examine the species of CoNS detected in samples; this is a study limitation and an area of research that merits further investigation.
Prevalence of AMR staphylococci
The prevalence of MR (62%), MDR (65%) and FQR (48%) amongst staphylococci was higher in the overall study period compared to previous work in healthy dogs, 11, 12 possibly due to longitudinal sampling. These data, however, were in line with reports in dogs with recurrent pyoderma exposed to antimicrobial therapy. 36 MRSP was isolated in 9% of dogs overall, which is double that previously reported in healthy dogs; 7, 8, 11, 12, [27] [28] [29] [30] likely due to recent antimicrobial and/or veterinary premises exposure and longitudinal sampling. A similar prevalence of MRSP (7.4%) was reported in a study of dogs admitted to a small animal hospital in which antimicrobial therapy and hospitalization were both identified as risk factors. 31 The initial detection of MRSP occurred immediately post-treatment in two dogs, and at one month post-treatment in four of 11 dogs. This may be because antimicrobial therapy will inhibit susceptible mucosal staphylococci, creating vacant ecological niches that can be filled by resistant variants transmitted from other hosts or the environment. MRSP was isolated in subsequent samples in the same four dogs, despite no further antimicrobials being prescribed, supporting the potential for extended carriage periods following treatment of clinical infections. 40 
Impact of FQ therapy
Fluoroquinolone therapy was a significant risk factor for the detection of MRS, MDR staphylococci and not surprisingly FQR staphylococci. Selection of MRS and MDR staphylococci is likely to have been due to co-selection and other studies have reported this for MRSA or MR-S. epidermidis in humans, and MRSA in dogs prescribed FQs. 35, [56] [57] [58] Furthermore, FQs may select for meticillinresistant isolates by upregulating adhesion factors, 57 increasing mutational rates or stimulating bacterial 'SOS' response, 59 or by repressing mecA regulator genes.
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Impact of beta-lactams Only CFX therapy was statistically significant for the detection of MDR staphylococci immediately post-treatment. It was surprising that beta-lactam therapy was not associated with MRS detection in multivariable models; however, results of previous risk factor analyses also have shown inconsistent results. A few studies have identified previous antimicrobial administration as a risk for MRS/MRSP carriage/infection, 31, 34, 38, 39, 61 but not individual drugs and/or classes, whereas other studies have not found a significant association at all. 37, 62, 63 Other studies, however, have reported beta-lactam therapy as a risk factor for MRSA infection in humans and dogs. 35, 64 Another study reported that beta-lactams were a risk for MRSP infections in dogs that were mainly receiving cephalosporins (less so AC) 65 and one study reported the detection of nasal MRSP in dogs within one week of CFX treatment in 10 dogs. 66 Penicillin-based or cephalosporin treatment also was found to be a risk for meticillin-resistant S. schleiferi infection in dogs. 54 In our study, AC appeared to have less effect on MRS detection than cephalosporins. The reasoning for this is likely to be multifactorial -including the level of antimicrobial resistance present before therapy, and the spectrum of activity, pharmacokinetics and pharmacodynamics of the different antimicrobials -and warrants further investigation. Another consideration could be treatment length, as the majority of dogs in the AC group only received up to one week of treatment, while those prescribed cephalosporins received two or more weeks. Although extended courses of antimicrobials would be expected to prolong selection pressure, 67 we found that duration of therapy was not significantly associated with the detection of resistance; however, this may be a result of small sample sizes.
Impact of clindamycin
Clindamycin therapy was not significantly associated with selection of AMR. Studies have reported that people with skin and soft tissue infections, treated with CD, had earlier clearance of MRSA mucosal/skin carriage 68 and were less likely to have persistent MRSA colonization; 69 treatment also was found to be protective against MDR MRSA environmental contamination. 70 Clindamycin was, however, a significant risk factor for reduced CoPS immediately after and at one month post-treatment in the present study. These findings suggest an extended effect compared to other tested antimicrobials. To the best of the authors' knowledge, the impact of antimicrobials on canine mucosal microbiota has not been reported previously; a human study described increased proportions of AMR nasal anaerobic bacteria for at least 12 months, following a 10 day course of CD.
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Antimicrobial exposure recovery period By one month post-treatment, for most treatment groups, the percentage of samples with the AMR outcomes had started to decline and had typically recovered to pre-treatment levels by three months post-treatment for AMR outcomes MRS and FQR. At this stage, there was no significant difference compared to all pre-treatment samples for all treatment groups. The decline in the percentage of samples with MDR staphylococci, however, was not as consistent. This finding was reflected in the multilevel modelling results, where FQ therapy was significant for MDR detection at one month post-treatment and CFX therapy was significant for MDR detection at three months post-treatment.
The mechanism of increased AMR following therapy and subsequent recovery was not investigated in this study, but is likely to be multifactorial. Staphylococci contain a number of MGEs that may be involved in horizontal transfer of AMR determinants between isolates. 72 SCCmec cassettes carry the mecA gene and may carry other AMR determinants, 26, 73 but generally are less mobile than other MGEs. 74 Furthermore, chromosomal mutations, giving rise to clinically relevant FQR, may take time to accumulate. 75 Therefore, selection and co-selection of pre-existing, possibly unisolated, MDR strains may have occurred. Additionally treatment with broad-spectrum antimicrobials may result in vacant mucosal niches that could be filled by exogenous strains acquired from the environment or in-contact hosts.
Other findings
In addition to antimicrobial therapy, a number of other factors were found to increase the risk of antimicrobial resistance. Dogs from multi-dog households were less likely to be positive for mucosal MRS in this study. This finding was unexpected, because sharing of staphylococci, including MRSP, has been reported between incontact individuals and pets, 41, 42, 76 particularly in multidog households. 77 Further, females were more likely to carry MDR isolates than males, a finding that disagrees with previous results for MRS. 36, 39 We found that dogs reported as eating animal stools or living with hosts with hospital contact had increased risk of detecting MDR staphylococci. These findings are line with other studies describing animal stools as a source of AMR Gram-positive bacteria, 78 and veterinary premises or hospital contact as a risk factor for MRS, often MDR staphylococci, 21, 79, 80 in dogs 31, 34, 81 or humans. 76, 82, 83 Limitations Although the population of dogs and samples was considered to be large, study power may have been limited due to small sample-sizes in treatment groups; however, we identified a number of significant risk factors. The P-value was not corrected based on the number of statistical tests (four) as this can increase Type II error. 84 Although our 'clinically-led' recruitment process was potentially biased, we accounted for any differences in pre-treatment variables within models. This study did not speciate the numerous CoNS detected from samples due to time and economic constraints. Unfortunately, we therefore cannot report on the longitudinal prevalence of potential CoNS pathogens, for example, S. schleiferi subspecies schleiferi following antimicrobial therapy. Longitudinal AMR prevalence, however, was analysed at the genus level and was therefore not affected.
This study prospectively examined the relationship between the persistence of staphylococcal AMR and antimicrobial therapy in 127 dogs (463 samples) over the full time-course and post-treatment exposure period. These results concur with previous reports that antimicrobial therapy increases the risk of AMR staphylococcal carriage, including MRS and MDR in dogs. 36 As the infecting isolates often originate from an individual's own mucosal flora, carriage of resistant staphylococci is a risk for resistant infections and therapeutic failure. This is of particular concern in dogs that may be immune-suppressed or predisposed to recurrent infections such as pyoderma. AMR mucosal staphylococci may be shared between individuals and environments including hospitals, home or the wider community, 42 meaning that adherence to strict hand hygiene and barrier nursing protocols could prevent dissemination, and have an impact upon veterinary and public health. Finally, our results have implications for antimicrobial prescribing guidelines and stewardship programmes for appropriate use of antibiotics for the veterinary community at large. 
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